Concert Pharmaceuticals Announces Patent Trial and Appeal Board Did Not Institute PGR Proceeding
12 January 2018 - 11:00PM
Business Wire
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced
that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent
and Trademark Office has decided not to grant the Company’s Post
Grant Review (PGR) petition challenging the validity of U.S. Patent
No. 9,662,335 (referred to as the ’335 patent) assigned to Incyte
Pharmaceuticals.
“We are disappointed that the PTAB has denied our petition on
the ’335 patent. This decision does not prohibit us from
challenging the validity of the patent at a later time in federal
court, and we will continue with our plans to develop CTP-543 for
alopecia areata. We don’t expect any disruption to our clinical
timelines,” said Roger Tung, President and CEO of Concert
Pharmaceuticals. “We remain committed to developing the first
FDA-approved treatment for alopecia areata; however, we are
reassessing whether to expand CTP-543 into additional
indications.”
In July 2017, Concert filed a PGR petition challenging the
validity of Incyte’s ’335 patent covering deuterated ruxolitinib
analogs. Documents relating to the PGR can be accessed online at:
http://www.concertpharma.com/technology-overview/intellectual-property/.
About ConcertConcert Pharmaceuticals is a clinical stage
biopharmaceutical company focused on applying its DCE Platform®
(deuterated chemical entity platform) to create novel medicines
designed to address unmet patient needs. The Company’s approach
starts with approved drugs in which deuterium substitution has the
potential to enhance clinical safety, tolerability or efficacy.
Concert has a broad pipeline of innovative medicines
targeting autoimmune and inflammatory diseases and central nervous
systems (CNS) disorders. For more information please visit
www.concertpharma.com or follow us on Twitter at @ConcertPharma or
on LinkedIn.
Cautionary Note on Forward Looking Statements
Any statements in this press release about our future
expectations, plans and prospects, including statements about the
strength of Concert's intellectual property, and other statements
containing the words "anticipate," "believe," "continue," "could,"
"estimate," "expect," "intend," "may," "plan," "potential,"
"predict," "project," "should," "target," "would," and similar
expressions, constitute forward-looking statements within the
meaning of The Private Securities Litigation Reform Act
of 1995. Actual results may differ materially from those indicated
by such forward-looking statements as a result of various important
factors, including factors discussed in the "Risk Factors" section
of our most recent Quarterly Report on Form 10-Q filed with
the Securities and Exchange Commission and in other
filings that we make with the Securities and Exchange
Commission. In addition, any forward-looking statements included in
this press release represent our views only as of the date of this
release and should not be relied upon as representing our views as
of any subsequent date. We specifically disclaim any obligation to
update any forward-looking statements included in this press
release.
Concert Pharmaceuticals Inc., the CoNCERT
Pharmaceuticals Inc. logo and DCE Platform are registered
trademarks of Concert Pharmaceuticals, Inc.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180112005093/en/
InvestorsConcert Pharmaceuticals, Inc.Justine Koenigsberg,
781-674-5284ir@concertpharma.comorMediaThe Yates NetworkKathryn
Morris, 914-204-6412kathryn@theyatesnetwork.com
Concert Pharmaceuticals (NASDAQ:CNCE)
Historical Stock Chart
From Apr 2024 to May 2024
Concert Pharmaceuticals (NASDAQ:CNCE)
Historical Stock Chart
From May 2023 to May 2024